Beta Bionics to Host Investor Event on June 22, 2025

About this update from Beta Bionics, Inc.

IRVINE, Calif. , April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025 , in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025 , in Chicago, IL. The event will begin at 7:00 am Central Time ( 8:00 am Eastern Time ) and conclude at approximately 8:30 am Central Time ( 9:30 am Eastern Time ). Members of the Company’s management team, led by Sean Saint , President and CEO, will present at the event. The agenda will include updates on commercial and financial performance, a demonstration of the patch pump in development, a review of the adaptive closed-loop algorithm, and new real-world clinical data. The Company invites investors to join the event via live webcast, a link to which will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com . Following the event, a replay of the webcast and its accompanying slide presentation will be archived on the Company’s website. Investors who would like to attend the event in-person will be required to register, which can be done by contacting the Company’s investor relations representative at [email protected] . About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com . Investor Relations: Blake Beber Head of Investor Relations [email protected] Media and Public Relations : Karen Hynes Vice President of Marketing [email protected] Source: Beta Bionics, Inc. Source: Beta Bionics, Inc.

View stock analysis, news, and events for Beta Bionics, Inc.